Patients Need A Biogenerics Pathway that DOESN'T Keep Them Waiting
WASHINGTON, April 16 /PRNewswire-USNewswire/ -- With dozens of biotech and drug company CEOs flying to Capitol Hill to meet with members of Congress, The Coalition for a Competitive Pharmaceutical Market (CCPM) today released a new ad urging members to keep the best interests of patients in mind as they consider legislation to create a workable approval pathway for safe, effective and affordable biogeneric medicines.
The ad, "What If Patients Had Wings?," states that meaningful biogenerics legislation should ensure that patients have access to life saving biogeneric medicines sooner rather than later. Such legislation must strike the balance of fostering innovation without harming patient access through excessive and unprecedented market exclusivity which simply extends brand monopolies and stifles competition. A bill that does not achieve this objective will be an empty promise to patients.
A broad coalition of patients, seniors, consumers, businesses, labor,
pharmacists, health plans, pharmacy benefit managers, and generics
supplemented this effort by sending a letter to House Energy and Commerce
Committee Chairman John Dingell and Ranking Member Joe Barton reiterating
its principles for workable and balanced biogenerics legislation that:
1. Empowers the FDA to use its expertise to determine on a case by case
basis what scientific data they need to approve comparable and
2. Does not include administrative barriers that impede FDA's ability to
approve safe and effective biogenerics.
3. Provides a clear framework for interchangeability that is immediately
operative and does not require additional congressional action.
4. Ensures predictability for when scientifically-proven, safe and
effective biogenerics can enter the marketplace.
5. Provides a clear and timely resolution to patent disputes and
prohibits frivolous suits that restrict access to biogenerics and
delay competition in the marketplace.
6. Creates a balanced process that encourages innovation by both brand
and generic companies and expands access to prescription medications
7. Does not create a system of endless monopoly pricing and no
opportunity for competition to enter the marketplace.
The following is the text of the latest CCPM ad:
What If Patients Had Wings?
Executives from the multi-billion dollar pharmaceutical and biotech
industry are descending on Congress...flying to Washington to make sure
their monopolies are protected.
Meanwhile countless Americans are struggling to pay for high-priced
These patients can't fly to Washington on their own, but they are making
their voices heard.
Numerous organizations representing patients, seniors, consumers, labor,
and businesses support legislation to establish a workable approval
pathway for biogenerics.
Americans need balanced legislation that fosters innovation without
excessive market exclusivity which does nothing more than extend
monopolies, stifle competition and keep patients waiting for affordable
BIO and PhRMA say that want a biogenerics pathway, but their policy is an
empty promise to patients.
CCPM supports public policies that facilitate timely access to affordable pharmaceuticals. Visit http://www.competitiverx.com for more information and a list of CCPM members.
Contact: Katie Braden Huffard, 202-255-5216;
Andrea Hofelich, 703-647-2495; Charles Cote, 202-207-3605
|SOURCE The Coalition for a Competitive Pharmaceutical Market(CCPM)|
Copyright©2008 PR Newswire.
All rights reserved